• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    2/14/23 8:16:01 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email
    SC 13G/A 1 d386020dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    IRADIMED CORPORATION

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    46266A109

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 46266A109

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Master Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      742,004 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      742,004 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      742,004 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.9% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      FI

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC (“Soleus Capital”) is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. Soleus Capital Group, LLC (“SCG”) is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 12,566,336 shares of common stock outstanding of the Issuer as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 3, 2022 (the “Form 10-Q”).


    CUSIP NO. 46266A109

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      742,004 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      742,004 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      742,004 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.9% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 12,566,336 shares of common stock outstanding of the Issuer as of October 31, 2022, as reported in the Form 10-Q.


    CUSIP NO. 46266A109

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Soleus Capital Group, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      742,004 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      742,004 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      742,004 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.9% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      OO

    FOOTNOTES

     

    (1)

    The shares of common stock reported in this row are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 12,566,336 shares of common stock outstanding of the Issuer as of October 31, 2022, as reported in the Form 10-Q.


    CUSIP NO. 46266A109

     

      1    

      NAMES OF REPORTING PERSONS

      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

      Guy Levy

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY  

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      SOLE VOTING POWER

     

      0

       6   

      SHARED VOTING POWER

     

      745,004 (1)

       7   

      SOLE DISPOSITIVE POWER

     

      0

       8   

      SHARED DISPOSITIVE POWER

     

      745,004 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      745,004 (1)

    10  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      5.9% (2)

    12  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      IN

    FOOTNOTES

     

    (1)

    Of the shares reported in this row, 3,000 shares are held by Mr. Guy Levy and 742,004 shares are held by Master Fund. Soleus Capital is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. SCG is the sole managing member of Soleus Capital. Mr. Guy Levy is the sole managing member of SCG. Each of SCG, Soleus Capital and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 12,566,336 shares of common stock outstanding of the Issuer as of October 31, 2022, as reported in the Form 10-Q.


    Item 1.

     

      (a)

    Name of Issuer

    Iradimed Corp.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    1025 Willa Springs Drive

    Winter Springs, FL 32708

    Item 2.

     

      (a)

    Name of Person(s) Filing

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Guy Levy

     

      (b)

    Address of Principal Business Office or, if none, Residence

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

      (c)

    Citizenship

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC - Delaware

    Guy Levy – United States

     

      (d)

    Title of Class of Securities

    Common Stock


      (e)

    CUSIP Number

    46266A109

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
    (e)    ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

    Soleus Capital Master Fund, L.P. (“Master Fund”) holds, as of the close of business on December 31, 2022, an aggregate of 742,004 shares of the common stock of the Issuer, and Mr. Guy Levy holds, as of the close of business on December 31, 2022, 3,000 shares of the common stock of the Issuer, for aggregate holdings by the Reporting Persons of 745,004 shares. As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the shares held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the Shares held by Master Fund.

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC or Soleus Capital Group, LLC is the beneficial owner of the shares of the common stock of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.


    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023     Soleus Capital Master Fund, L.P.
        By:   Soleus Capital, LLC, its General Partner
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023     Soleus Capital, LLC
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023     Soleus Capital Group, LLC
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: February 14, 2023    

    /s/ Guy Levy

        Name:   Guy Levy

    Footnotes:

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

    Get the next $IRMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump System

      WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ:IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed's unique position as the world's only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005. The MRidium® 3870 is poised to strengthen Iradimed's leadership for MRI-compatible infusion, addressing growing demands for safe and reliable fluid delivery in diagnostic imagi

      5/29/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on iRadimed with a new price target

      Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

      4/12/23 9:17:10 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Glenn John converted options into 5,796 shares and covered exercise/tax liability with 1,412 shares, increasing direct ownership by 50% to 13,151 units (SEC Form 4)

      4 - IRADIMED CORP (0001325618) (Issuer)

      6/23/25 8:00:21 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 4 filed by CHIEF FINANCIAL OFFICER Glenn John

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/7/25 4:10:04 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Hawkins James B converted options into 1,196 shares, increasing direct ownership by 4% to 33,545 units (SEC Form 4)

      4/A - IRADIMED CORP (0001325618) (Issuer)

      4/4/25 4:45:06 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    SEC Filings

    See more
    • iRadimed Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - IRADIMED CORP (0001325618) (Filer)

      6/23/25 9:49:42 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • iRadimed Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IRADIMED CORP (0001325618) (Filer)

      5/29/25 4:15:13 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by iRadimed Corporation

      10-Q - IRADIMED CORP (0001325618) (Filer)

      5/5/25 4:30:33 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

      WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

      10/6/22 4:05:00 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

      Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

      6/1/22 9:35:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      11/14/24 3:35:27 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/13/24 4:25:25 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

      SC 13G/A - IRADIMED CORP (0001325618) (Subject)

      2/12/24 12:03:30 PM ET
      $IRMD
      Medical/Dental Instruments
      Health Care

    $IRMD
    Financials

    Live finance-specific insights

    See more
    • IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

      Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025. WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) announced today its

      5/5/25 7:00:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ:IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025".  The corrected release follows: IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Monday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conferen

      4/28/25 9:53:08 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care
    • IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025

      WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI1cddc009ba2b427a81ea445f5669adffOnce registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-

      4/28/25 8:30:00 AM ET
      $IRMD
      Medical/Dental Instruments
      Health Care